CHF7.47
3.89% day before yesterday
SIX Swiss Exchange, Aug 08, 05:31 pm CET
ISIN
IT0004147952
Symbol
NWRN

Newron Pharmaceutical Target price 2025 - Analyst rating & recommendation

Newron Pharmaceutical Classifications & Recommendation:

Buy
88%
Hold
13%

Newron Pharmaceutical Price Target

Target Price CHF13.06
Price CHF7.47
Potential
Number of Estimates 5
5 Analysts have issued a price target Newron Pharmaceutical 2026 . The average Newron Pharmaceutical target price is CHF13.06. This is higher than the current stock price. The highest price target is
CHF26.25 251.41%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Newron Pharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Newron Pharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Newron Pharmaceutical stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million CHF 48.38 11.19
467.17% 76.86%
EBITDA Margin 51.30% -236.70%
140.67% 561.38%
Net Margin 30.84% -280.22%
117.23% 1,008.65%

5 Analysts have issued a sales forecast Newron Pharmaceutical 2025 . The average Newron Pharmaceutical sales estimate is

CHF11.2m
Unlock
. This is
76.86% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF15.0m 68.94%
Unlock
, the lowest is
CHF6.7m 86.11%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF48.4m 467.17%
2025
CHF11.2m 76.86%
Unlock
2026
CHF12.4m 11.05%
Unlock
2027
CHF6.8m 44.92%
Unlock
2028
CHF168m 2,350.28%
Unlock
2029
CHF193m 14.76%
Unlock
2030
CHF184m 4.29%
Unlock
2031
CHF226m 22.39%
Unlock
2032
CHF250m 10.97%
Unlock

5 Analysts have issued an Newron Pharmaceutical EBITDA forecast 2025. The average Newron Pharmaceutical EBITDA estimate is

CHF-26.5m
Unlock
. This is
206.76% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF-24.0m 196.54%
Unlock
, the lowest is
CHF-29.4m 218.58%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF24.8m 330.67%
2025
CHF-26.5m 206.76%
Unlock
2026
CHF-11.1m 58.03%
Unlock
2027
CHF-2.8m 74.44%
Unlock
2028
CHF138m 4,970.44%
Unlock
2029
CHF160m 15.89%
Unlock
2030
CHF148m 8.00%
Unlock
2031
CHF186m 26.09%
Unlock
2032
CHF208m 11.82%
Unlock

EBITDA Margin

2024 51.30% 140.67%
2025
-236.70% 561.38%
Unlock
2026
-89.45% 62.21%
Unlock
2027
-41.51% 53.59%
Unlock
2028
82.52% 298.80%
Unlock
2029
83.33% 0.98%
Unlock
2030
80.10% 3.88%
Unlock
2031
82.52% 3.02%
Unlock
2032
83.15% 0.76%
Unlock

5 Newron Pharmaceutical Analysts have issued a net profit forecast 2025. The average Newron Pharmaceutical net profit estimate is

CHF-31.4m
Unlock
. This is
310.25% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF-29.8m 299.66%
Unlock
, the lowest is
CHF-33.0m 320.91%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF14.9m 197.71%
2025
CHF-31.4m 310.25%
Unlock
2026
CHF-15.3m 51.32%
Unlock
2027
CHF-5.2m 66.08%
Unlock
2028
CHF86.7m 1,774.52%
Unlock
2029
CHF100m 15.61%
Unlock
2030
CHF98.8m 1.46%
Unlock
2031
CHF126m 27.04%
Unlock
2032
CHF138m 10.05%
Unlock

Net Margin

2024 30.84% 117.23%
2025
-280.22% 1,008.65%
Unlock
2026
-122.83% 56.17%
Unlock
2027
-75.58% 38.47%
Unlock
2028
51.70% 168.40%
Unlock
2029
52.09% 0.75%
Unlock
2030
53.62% 2.94%
Unlock
2031
55.66% 3.80%
Unlock
2032
55.20% 0.83%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share CHF 0.80 -1.57
193.02% 296.25%
P/E negative
EV/Sales 16.24

5 Analysts have issued a Newron Pharmaceutical forecast for earnings per share. The average Newron Pharmaceutical EPS is

CHF-1.57
Unlock
. This is
296.25% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF-1.49 286.25%
Unlock
, the lowest is
CHF-1.65 306.25%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF0.80 193.02%
2025
CHF-1.57 296.25%
Unlock
2026
CHF-0.77 50.96%
Unlock
2027
CHF-0.26 66.23%
Unlock
2028
CHF4.35 1,773.08%
Unlock
2029
CHF5.02 15.40%
Unlock
2030
CHF4.95 1.39%
Unlock
2031
CHF6.29 27.07%
Unlock
2032
CHF6.92 10.02%
Unlock

P/E ratio

Current 9.34 211.67%
2025
-4.75 150.87%
Unlock
2026
-9.76 105.47%
Unlock
2027
-28.81 195.18%
Unlock
2028
1.72 105.97%
Unlock
2029
1.49 13.37%
Unlock
2030
1.51 1.34%
Unlock
2031
1.19 21.19%
Unlock
2032
1.08 9.24%
Unlock

Based on analysts' sales estimates for 2025, the Newron Pharmaceutical stock is valued at an EV/Sales of

16.24
Unlock
and an P/S ratio of
12.82
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.76 86.64%
2025
16.24 331.85%
Unlock
2026
14.62 9.95%
Unlock
2027
26.55 81.56%
Unlock
2028
1.08 95.92%
Unlock
2029
0.94 12.87%
Unlock
2030
0.99 4.48%
Unlock
2031
0.81 18.29%
Unlock
2032
0.73 9.89%
Unlock

P/S ratio

Current 2.97 87.04%
2025
12.82 332.16%
Unlock
2026
11.54 9.95%
Unlock
2027
20.96 81.56%
Unlock
2028
0.86 95.92%
Unlock
2029
0.75 12.86%
Unlock
2030
0.78 4.48%
Unlock
2031
0.64 18.30%
Unlock
2032
0.57 9.89%
Unlock

Current Newron Pharmaceutical Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RX SECURITIES
Locked
Locked
Locked May 11 2025
BAADER HELVEA EQUITY RESEARCH
Locked
Locked
Locked Mar 31 2025
RX SECURITIES
Locked
Locked
Locked Mar 31 2025
RX SECURITIES
Locked
Locked
Locked Jan 05 2025
BAADER HELVEA EQUITY RESEARCH
Locked
Locked
Locked Dec 12 2024
Analyst Rating Date
Locked
RX SECURITIES:
Locked
Locked
May 11 2025
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
Locked
Mar 31 2025
Locked
RX SECURITIES:
Locked
Locked
Mar 31 2025
Locked
RX SECURITIES:
Locked
Locked
Jan 05 2025
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
Locked
Dec 12 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today